Jil Swanson, PA
Physician Assistant · Washington, PANPI 1386792422
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 61.1% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $20,807, 7.9 times the $2,650 reported in 2021. Among physician assistant clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,045 payments — averaging $41.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$27K
- AbbVie$3K
- Amgen$3K
- Sanofi$2K
- Lilly USA, LLC$1K
- E.r. Squibb & Sons, L.L.C.$954
- plus $6K from 25 others
What the payments were for
- Consulting fees$3,4638%
- Speaking & faculty fees$19,57545%
- Travel & lodging$2,4616%
- Food & beverage$17,74141%
- Education$5631%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 201 | $26,749 |
| AbbVie | 298 | $3,207 |
| Amgen | 56 | $2,924 |
| Sanofi | 43 | $2,347 |
| Lilly USA, LLC | 60 | $1,147 |
| E.r. Squibb & Sons, L.L.C. | 46 | $954 |
| Novartis | 34 | $857 |
| Galderma Laboratories, L.p. | 36 | $761 |
| UCB, Inc. | 39 | $596 |
| Pfizer | 35 | $573 |
| LEO Pharma Inc. | 21 | $468 |
| Journey Medical Corporation | 25 | $464 |
| Incyte Corporation | 22 | $461 |
| Sun Pharmaceutical Industries Inc. | 24 | $432 |
| Biofrontera Inc. | 19 | $359 |
| Regeneron Healthcare Solutions, Inc. | 13 | $344 |
| Mayne Pharma Commercial LLC | 10 | $205 |
| Dermavant Sciences, Inc. | 14 | $191 |
| VYNE Pharmaceuticals Inc. | 9 | $141 |
| Boehringer Ingelheim | 7 | $121 |
| EPI Health, LLC | 5 | $87 |
| Dermira, Inc. | 4 | $84 |
| Verrica Pharmaceuticals Inc. | 5 | $84 |
| Organon | 8 | $79 |
| Botanix SB Inc | 2 | $42 |
| Arcutis Biotherapeutics, Inc. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $24 |
| Nabriva Therapeutics, PLC | 1 | $19 |
| Mission Pharmacal Company | 1 | $15 |
| Stemline Therapeutics Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,803 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 40 | $174,551 |
| Clobetasol Propionate | 77 | $2,817 |
| Fluorouracil | 19 | $1,559 |
| Metronidazole | 12 | $1,286 |
| Desonide | 17 | $1,035 |
| Ketoconazole | 63 | $818 |
| Clindamycin Phosphate | 14 | $799 |
| CiclopiroxCiclopirox Olamine | 40 | $693 |
| Triamcinolone Acetonide | 76 | $664 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 29 | $538 |
| Doxycycline Hyclate | 29 | $394 |
| Mupirocin | 29 | $155 |
| Hydrocortisone | 13 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $2,924 | $174,55140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Other physician assistant in Washington
- Joshua TrbovichWashington$144K
- Jeffrey CameronWashington$89K
- Maria QuerrieraWashington$22K
- Amanda WebbWashington$19K
- Erin CrownState College$1.2M
- Tricia BootsCranberry Twp$313K
- Melissa FerrariPhiladelphia$223K
- Jason OberdickWexford$206K
- Justine RobertsMurrysville$173K
- Allison BoydErie$163K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.